Search
forLearn
5 / 801 resultslearn Isostearamidopropyl
learn dehydroepiandrosterone
learn 1,2-Hexanediol
learn HYDROXYPROPYLGLUCONAMIDE
Research
5 / 1000+ results
research Female pattern hair loss
Hair loss in women is genetic, diagnosed by examination and biopsy, and treated with minoxidil, finasteride, or transplantation.
research Systematic Literature Review on Troubleshooting Delivery of Production Product Using n-Vehicle with Vogel Total Difference Approach Method
The Vogel Total Difference Approach Method helps reduce shipping costs in production delivery.
research Analysis of the FGF gene family provides insights into aquatic adaptation in cetaceans
Whale genes show changes that help them live in water, like less hair and better flippers.
research Glutamic acid promotes hair growth in mice
Glutamic acid helps increase hair growth in mice.
research Emerging lipid–polymer hybrid nanoparticles for genome editing
Lipid–polymer hybrid nanoparticles can improve genome editing delivery and outcomes.
Community Join
5 / 1000+ resultscommunity Norwood 1 to 3 is normal, and NOT balding
Norwood 1-3 hair loss is considered normal in Russia and not balding. Using finasteride for Norwood 1-3 is seen as unnecessary and risky.
community 4 months progress on topicals and vitamins !
A 24-year-old male has been using 0.1% finasteride and 5% minoxidil daily for four months, added dermarolling and topical dutasteride, and sees hair regrowth, improving from a Norwood scale 4a to 3a. He wants to optimize his hair loss treatment routine.
community Anyone knows a legitimate online source/distributer of 17α-estradiol (Alfatradiol) powder?
The conversation is about finding a legitimate online source for 17α-estradiol (Alfatradiol) powder to make a 0.1% solution for hair loss treatment. A user suggests Anagenica as a source.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.